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Abstract 
Sleep disturbance and mood dysregulation are widely-experienced and costly concerns, even at 
the sub-clinical level. Sleep disturbance and mood dysregulation are mechanistically and 
diagnostically linked through circadian rhythms. Blue light has strong influence on entraining 
circadian rhythms, and controlling blue light has become a target of many interventions aiming 
to improve sleep and mood. The use of amber lenses, which selectively block blue wavelengths 
of light, are one such intervention. Past studies have found that amber glasses can be a helpful 
adjunct treatment for some severe mental illness (e.g., bipolar disorder), but research has been 
inconclusive about how amber glasses affect people with sub-clinical sleep and mood concerns. 
Using a randomized crossover design with a wide variety of objective and self-report measures, 
the present study examined the effect of blue-blocking amber glasses on sleep quality, latency, 
efficiency, and duration, as well as positive and negative affect in 15 participants over a 14-day 
period. Overall, our results did not support our hypothesis that amber glasses would increase 
sleep quality, duration, and efficiency, and decrease sleep latency, although minor but non-
significant positive changes were observed on some sleep outcome variables. Our results did, 
however, provide strong preliminary evidence that amber glasses enhance positive mood at 
night, and some evidence that amber glasses decrease negative mood in the morning. This study 
was limited by a small sample size, large interpersonal variation, and some participant 
noncompliance. Future studies should work to address these limitations, as well as solve extant 




AMBER GLASSES, SLEEP, & AFFECT 
 4 
The Effect of Blue-Light-Blocking Amber Glasses on Sleep and Affect 
 Sleep dysregulation plays a transdiagnostic role in a wide range of physical health 
outcomes—cancer (Blask, 2009), obesity (Garaulet & Madrid, 2010), heart disease (Stevens et 
al., 2013), illness or injury recovery (Zelinski et al., 2014), and jet lag (Brown et al., 2009)—and 
mental health outcomes—depression (Esaki et al., 2016; Salva & Hartley, 2012), bipolar disorder 
(Henriksen et al., 2016; van der Lely et al., 2015), suicide (Bernert & Joiner, 2007), memory 
(Zelinski et al., 2014), energy (Franke et al., 2009), and alertness (Sasseville et al., 2015). Sleep 
dysregulation is linked to mental health outcomes through biochemical pathways that regulate 
circadian rhythm (Salva & Hartley, 2012). Given the strong linkages between mental health 
outcomes, sleep, and circadian rhythm, low-cost sleep hygiene interventions have been 
developed to improve sleep duration, rhythmicity, and quality, as well as mood and cognition. 
One such intervention—light manipulation—controls ambient blue light, which is a stimulus for 
the biochemical pathways that entrain circadian rhythm (Salva & Hartley, 2012). Some light 
manipulation interventions increase participant exposure to blue light during the day, which has 
been shown to improve mood and alertness (Sasseville et al., 2015; Szabó et al., 2004). 
However, the light manipulation intervention examined in this paper uses blue-light-blocking 
amber lenses to lessen exposure to blue light before bedtime (Kimberly & James R., 2009). The 
introduction describes the biological mechanisms that link blue light to the different health 
outcomes of interest, outlines the results of previous research that examined light manipulation 
across the health outcomes of interest, and delineates the aims and contributions of the present 
study to the light intervention literature.  
How Blue Light Affects Sleep 
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Blue light modulates many circadian rhythms within the body through a retinal pathway 
that connects to the body’s master clock. In most organisms, a biological clock is present that 
controls bodily processes with circadian rhythmicity (Salva & Hartley, 2012; Wirz-Justice, 
2009). A circadian rhythm is the endogenous, continuous 24-hour oscillation of any 
physiological variable (Guido et al., 2010; Wirz-Justice, 2007). The sleep/wake cycle is one such 
circadian rhythm, but body temperature and many hormones also oscillate on a 24-hour cycle, 
and are therefore also circadian rhythms (Guido et al., 2010; Wirz-Justice, 2007). The 
suprachiasmatic nucleus (SCN), which is located in the anterior hypothalamus, maintains 
intrinsic circadian rhythms in humans and is therefore referred to as the master circadian clock 
(Guido et al., 2010). The SCN controls circadian rhythms through both the oscillating activation 
and deactivation of specific clock genes, and through activation of the pineal gland, which 
controls the rhythmic production of melatonin (Vela-Bueno et al., 2007; Wirz-Justice, 2009). 
Melatonin is a neurohormone that has several functions related to reinforcing and stabilizing 
circadian rhythms, including the sleep/wake cycle (Vela-Bueno et al., 2007; Wirz-Justice, 2009).   
This system functions endogenously without the need of external stimuli; however, 
external stimuli regulate and reset daily circadian rhythms. The SCN, though it maintains a free-
running 24-hour rhythm without external stimuli, it is entrained and reset daily by external 
zeitgebers (“time givers”)(Asarnow et al., 2014; Macchi & Bruce, 2004; Wirz-Justice, 2009). 
Because circadian rhythms evolved corresponding to day and night patterns, light is a 
particularly strong external zeitgeber, especially blue wavelengths of length (Guido et al., 2010; 
Harvey et al., 2011). Other external zeitgebers, such as consistent social interactions or a work 
schedule, also entrain circadian rhythms (Frank, 2007; Guido et al., 2010). Blue light affects this 
pathway because the retina contains specific cells that use a photoreceptor, melanopsin, which is 
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particularly sensitive to blue wavelengths (Salva & Hartley, 2012). Melanopsin receptor cells 
connect from the eye to the body’s master clock in the SCN (Macchi & Bruce, 2004; Wirz-
Justice, 2007). Both exposure to daylight in the morning and exposure to artificial blue light can 
reset the body’s biological clock through this pathway (Salva & Hartley, 2012; Vela-Bueno et 
al., 2007).  
Two systems interact to control the sleep/wake cycle in humans: the homeostatic process 
(process S) and circadian rhythms (process C) (Asarnow et al., 2014; Harvey et al., 2011). The 
homeostatic process relies on the gradual increase of sleep pressure over the course of the day—
making it more likely for a person to fall asleep—and the decrease of sleep pressure as a result of 
sleep (Salva & Hartley, 2012). The process C circadian rhythm aligns with day/night cycles, with 
light acting as a zeitgeber (Salva & Hartley, 2012). Light suppresses the SCN, pineal gland, and 
subsequent melatonin production; the melatonin suppression corresponds to the wake phase of 
the sleep/wake cycle. Darkness up-regulates the SCN, pineal gland, and melatonin and 
contributes to sleep onset and maintenance (Guido et al., 2010; Salva & Hartley, 2012; Vela-
Bueno et al., 2007). Under normal conditions, process S and process C are synchronous and, as a 
result, sleep quality is the highest (Harvey et al., 2011; Salva & Hartley, 2012). When process S 
and process C become desynchronous, sleep can become disturbed (Asarnow et al., 2014; 
Harvey et al., 2011). Because artificial blue light acts on the circadian pathway, the sleep/wake 
circadian rhythm is particularly susceptible to disturbance by environmental influences. Artificial 
blue light has been shown to enhance feelings of alertness even at night (Revell et al., 2006; 
Sasseville et al., 2015), suppress melatonin (Lockley et al., 2003; Vela-Bueno et al., 2007), and 
delay phase of circadian rhythms (Lockley et al., 2003).   
How Blue Light Effects Mood 
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Sleep disturbance is so common amongst those with mood dysregulation that it is considered 
one of the core symptoms of mood disorders (Salva & Hartley, 2012). At the sub-clinical level, 
sleep disturbance—which can be caused by excess blue light exposure—is linked to large 
increases negative mood (Harvey et al., 2011). Sleep disturbance not only increases negative 
emotional response, but also decreases positive emotional response (Harvey et al., 2011). Sleep 
disturbance also decreases medial-prefrontal cortex activity, which leads to impaired top down 
regulation and executive functioning, two important abilities for emotional control (Harvey et al., 
2011).  
Sleep disturbance modulates affect because the mechanisms that maintain adaptive affect—
genes and neurotransmitters—are deeply intertwined with sleep/wake circadian rhythm 
maintenance. For instance, genes that are important for circadian rhythm creation and 
maintenance have been linked to bipolar disorder, major depressive disorder, and seasonal 
affective disorder (Harvey et al., 2011). Sleep disturbance from excess blue light causes 
disruptions in the oscillating transcription and translation of these shared genes, affecting mood 
(Harvey et al., 2011). Furthermore, neurotransmitters involved in mood psychopathology—
serotonin and dopamine—are involved in the maintenance sleep/wake cycle and, themselves, 
oscillate in a 24-hour cycle. Serotonin plays a role in attention, cognition, and information 
processing (Harvey et al., 2011). Dysregulation of serotonin is a well-supported pathway to 
mood disorder, as serotonin plays a key role in the diathesis-stress model of depression, wherein 
interactions between environmental stress and serotonin polymorphisms confer greater risk for 
depression development (Harvey et al., 2011). The SCN contains a dense concentration of 
serotonergic receptors, and serotonin acts on the SCN to stabilize circadian rhythms (Harvey et 
al., 2011). Dually, circadian rhythms also modulate serotonin, as serotonin and serotonergic 
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receptor activity oscillate on a 24-hour cycle endogenously and are modulated by light and 
season (Harvey et al., 2011). This bidirectional circadian and serotonin interaction is a main 
feature of a conceptual model of depression as proposed by Mistlberger et al (Mistlberger et al., 
2000).  
Dopamine plays a role in motivation, reward processing, and pleasure dysregulation (Harvey 
et al., 2011). Dopamine dysregulation is strongly involved in mood disorders, and contributes to 
the flawed reward processing inherent to anhedonia, a core symptom of depression (Harvey et 
al., 2011). Dopamine, like serotonin, is linked to circadian rhythms maintenance in a number of 
ways. Dopaminergic reward activation and positive mood oscillate diurnally, indicating that they 
are controlled by circadian rhythms (Harvey et al., 2011). Dopamine, like serotonin, helps 
entrain circadian rhythms in the pathway from the retina to the SCN (Harvey et al., 2011). An 
additional way that dopamine is linked to sleep/wake circadian rhythms is through melatonin, 
which downregulates dopamine release; excess dopamine, dually, downregulates melatonin 
synthesis (Guido et al., 2010). Additionally, dopamine is linked to the sleep/wake circadian 
rhythm through light, which upregulates dopamine production in the retina (Guido et al., 2010). 
Dopamine plays a major role in regulating the retinal circadian clock so that the retinal cones 
receive much less light at night than during the day (Ribelayga et al., 2008). In sum, a large body 
of evidence supports that both serotonin and dopamine are deeply involved in circadian rhythms 
and sleep, outlining a mechanism through which sleep and circadian rhythm disruption can 
impact mood.  
Interventions for Sleep and Mood Improvement 
Inappropriately timed or irregular exposure to light and dark plays a large role in the 
pathology of mood disorders and in emotional dysregulation (Asarnow et al., 2014; Harvey et al., 
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2011). However, process C and process S, which control the sleep/wake cycle, are open systems 
that respond to environmental stimuli; this is promising therapeutically, as it is possible to 
modify mood through controlling light and sleep (Asarnow et al., 2014; Harvey et al., 2011). For 
example, serotonin and dopamine are both circadian rhythms controlled by the SCN, which is 
modulated by light conditions. Therefore, interventions that modulate light, especially blue light, 
should impact these neurotransmitters and subsequent mood non-pharmacologically.  
Benzodiazepines are the most commonly prescribed medication for sleep regulation, and 
while they are effective, they also are highly addictive, and patients easily become tolerant to 
them (Riemann et al., 2015). Antihistamines are also commonly prescribed for sleep regulation, 
and though they are not addictive, they are associated with liver and heart dysfunction, in 
addition to other side-effects (Riemann et al., 2015). Exogenous melatonin is also often 
administered for the regulation of sleep, but studies so far show only minor positive changes in 
sleep duration, quality, and onset latency (Salva & Hartley, 2012; Vela-Bueno et al., 2007). 
Given that the most commonly prescribed medications for addressing sleep disturbance are either 
not suitable for long-term use or do not make substantial improvements to sleep disturbances, 
non-pharmacological options for sleep hygiene are needed.  
 Two common psychotherapies designed to address sleep disturbance aim to enhance 
consistent in sleep hygiene and daily routine. Cognitive Behavioral Therapy for Insomnia (CBT-
I) aims to improve sleep habits and hygiene, as well as address anxieties about sleep that 
exacerbate sleep disturbance (Mitchell et al., 2012). CBT-I effect sizes range from comparable to 
more effective at improving sleep hygiene and mood symptoms than common pharmacological 
treatments (Asarnow et al., 2014). Interpersonal and Social Rhythm Therapy (IPSRT) aims to 
regulate social and interpersonal zeitgebers (e.g. daily routine, romantic relationships) (Frank, 
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2007), the disturbance of which also often disturb the rhythmicity of exposure to stronger 
zeitgebers, such as light (Asarnow et al., 2014). There is only evidence that IPSRT is effective 
for the amelioration of bipolar disorder symptoms, though it is hypothesized to also effectively 
treat depressive symptoms (Asarnow et al., 2014).  
 Light and dark therapy interventions—bright light exposure and light restriction—are 
also common treatments designed to ameliorate sleep disturbance. The aims of light therapy are 
to resynchronize the circadian clock with the day/night cycle, to align sleep and wake with 
desired times, and to enhance mood (Wirz-Justice, 2007). Bright light exposure, in which 
patients are exposed to bright light in concordance with their circadian rhythms, is effective at 
relieving symptoms associated with seasonal depression, major depressive disorder, suicidal 
ideation, post-partum depression, and chronic fatigue (Asarnow et al., 2014; Salva & Hartley, 
2012). Bright light exposure also delays sleep phase, enhances alertness, and delays melatonin 
rhythms (Lockley et al., 2003; Revell et al., 2006). 
Light restriction interventions aim to reduce exposure to bright light, especially blue light, 
approaching sleep in concordance with natural circadian rhythm (Asarnow et al., 2014). 
Foundational light restriction therapies placed patients in complete darkness, and were used to 
successfully reduce manic symptoms in patients with bipolar disorder (Asarnow et al., 2014). 
More modern techniques of light reduction involve the filtering of blue wavelength of light with 
amber glasses during the evening (Burkhart & Phelps, 2009). One study found that amber glasses 
worn before sleep thwarted LED-induced melatonin suppression, increased subjective sleepiness, 
and decreased alertness, indicating that blue glasses successfully reduce signal to the SCN (van 
der Lely et al., 2015). Similar studies have replicated these sleep quality improvements, and 
found additional mood improvements (Kimberly & James R., 2009). Other similar studies report 
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no significant differences between control and experimental conditions on sleep quality or mood 
measures (Esaki et al., 2017). Amber glasses are typically used as an adjunct treatment for mood 
disturbances, and aside from the occasionally reported head discomfort, amber glasses are safe 
for long-term use (Esaki et al., 2016; Salva & Hartley, 2012). The current dearth of randomized 
control trails assessing the effect of blue-blocking amber glasses on sleep and mood, especially 
on those with sub-clinical sleep and mood concerns, limit the ability to draw conclusions on the 
efficacy of this intervention. 
The Present Study: Effects of Amber Glasses on Melatonin, Sleep, and Mood 
The present study aims to evaluate the effect of blue-light-blocking amber glasses on 
sleep duration, quality, efficiency, and latency, and affect over the course of many nights of 
sleep. We hypothesized that people in the amber glasses condition will show significantly better 
quality of sleep based on both subjective report (e.g. sleep diary, daily ratings of energy) as well 
as objective measures (e.g. actigraphy and oximetry). We also hypothesized that participants in 
the amber condition will show significantly more positive affect, and lower negative affect 
(depression and irritability), based on subjective report using well established rating scales. 
Exploratory aims include looking at the agreement between subjective (sleep diary, energy 
ratings) and objective (actigraphy and oximetry) measures of sleep constructs. This study will 
provide more evidence in the evaluation of amber glasses as a helpful adjunct treatment for those 
with sub-clinical levels of sleep and mood concerns.  
Method 
Participants 
The 15 participants included in this study were a community sample. Participants were 
recruited through flyers and website recruitment ads targeting adults in the Chapel Hill 
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community. Participants interested in the study were encouraged to e-mail or call the study 
coordinator for additional information about participating in the study. Participants received 
$100 in compensation at the end of each week during their participation. Participants received a 
$50 bonus at the end of the study for completing all questionnaires and the sleep log. Participants 
were provided with parking for two nights in the sleep lab. Additionally, participants were given 
$15 for an evening meal each night while in the sleep laboratory as well as provided with 
breakfast food in the morning. 
Inclusion criteria for participants were that they were in good physical health and 
proficient in written and spoken English. Participants also must have reported average total sleep 
time of less than 9 hours a night so that nights spent in the sleep lab would not result in sleep 
deprivation. Exclusion criteria included: taking regular medication affecting sleep and/or mood; 
traveling across more than two time zones within the past month; smoking more than 5 cigarettes 
per day; using caffeine excessively (more than 2 cups at one time or >500 mg daily); having a 
current DSM-5 Disorder; using street drugs at the time of the study; having a history of sleep 
disorder, bipolar disorder, psychosis, or seizure disorder; having chronic medical condition; and 
working under a night shift schedule within the past 2 months. Exclusion criteria were based on 
factors that might change melatonin production, thus altering sleep/wake circadian rhythms, not 
factors that would change risk of participation. 
Measures and Equipment 
State Affect. The Positive and Negative Affective Schedule (PANAS) (Watson et al., 1988) 
was used to assess state affect twice each day. The PANAS consists of 20 items, 10 of which 
assess positive affect (e.g. inspired, active, attentive) and 10 of which assess negative affect (e.g. 
guilty, scared, hostile). Items are rated from a scale of 1 (Very slightly or not at all) to 5 
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(Extremely) for how participants feel at the moment. Higher scores correspond to higher levels 
of positive or negative affect. Cronbach’s alpha for the negative affect items was .87 and 
Cronbach’s alpha for the positive affect items was .90 in the original sample (Watson et al., 
1988).  Percentage of Maximum Possible (POMP) scores were computed for each of the two 
subscales to aid in ease of interpretation. 
Subjective Measures of Sleep. Participants filled out two subjective measures of sleep every 
day, and one extra subjective measure of sleep on the two sleep lab days only. Participants filled 
out the Leeds Sleep Evaluation Questionnaire (LSEQ) every morning for the 14 days of the 
study (Parrott & Hindmarch, 1978) to examine sleep quality and latency. The LSEQ is a 10 item, 
subjective, self-report questionnaire with items rated on a sliding scale between two options. For 
example, one question assessing ease of getting to sleep (i.e. “How would you describe the way 
you fell asleep last night in comparison to usual?”) is answered on sliding scales between “more 
difficult than usual” and “easier than usual.” The LSEQ can be scored on three different 
subscales, each of which examines a different aspect of sleep: ease of getting to sleep (GTS 
subscale; items 1-3), overall quality of sleep (QOS subscale; items 4 and 5), and behavior 
following wakening (BFW subscale; items 8-10). Percentage of Maximum Possible (POMP) 
scores were computed for each of the four subscales to aid in ease of interpretation. In this study, 
the GTS subscale is used to measure sleep latency, and the other two LSEQ subscales are used to 
measure sleep quality. The GTS subscale is rated such that higher scores indicate more ease in 
falling asleep, or lower sleep latency. The QOS subscale is rated such that higher scores indicate 
better overall sleep quality. The BFW is rated such that higher scores indicate more alertness and 
more coordination upon waking.  
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Participants filled out the Pittsburgh Sleep Quality Index (PSQI) twice—once in the morning 
and once in the evening—on each of the two sleep lab days. The PSQI measured sleep duration, 
latency, and quality over the course of the week prior. The PSQI is a 20 item, subjective, self-
report questionnaire with several kinds of items. One item asks participants to average sleep 
duration during the week, and one item asks participants to estimate the average time it took 
them to fall asleep, or sleep latency. One item asks participants to rate their sleep quality over all; 
this item is rated on a scale from 1 (very good) to 4 (very bad).  
Objective Measures of Sleep. Two objective biological measures of sleep were used in this 
study: GENEActiv and WatchPAT 300 devices. Participants were asked to wear Activinsights 
GENEActiv actigraphy watches every day for the duration of the 14-day study. GENEActiv 
watches measured movement, light exposure, and body temperature. Using the GENEActiv 
Sleep Macro v31 in Excel produced by the GENEActiv manufacturer, summary statistics of 
sleep duration and efficiency were determined for each of the 14 days of the study.  
WatchPAT 300 devices from the Biobehavior Lab at the School of Nursing at UNC, the 
sleep lab where the participants slept for Sleep Phase I and II, were used to objectively measure 
sleep in addition to the GENEActiv devices. The WatchPAT 300 devices were used to 
noninvasively and objectively measure sleep using peripheral arterial tone and oxygen perfusion. 
Data from WatchPAT 300 were analyzed by the WatchPAT 300 software and the following 
summary statistics were computed: sleep duration in minutes, sleep latency (time in minutes 
between getting in bed and falling asleep), and number awakenings during the night, REM 
latency (time between falling asleep and start of first REM period), mean oxygen saturation of 
blood over the course of a night of sleep (higher scores indicating more perfusion), and mean 
heart rate over the course of a night of sleep.  
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Colored Lenses. Participants wore Uvex Skyper Anti-Fog Safety Glasses with grey lenses 
(S2821XP) and with amber lenses (S1933X). Participants were randomized to a starting color for 
the first glasses phase (three days), then switched to the other glasses color for the second glasses 
phase (three days). Transmittance analyses were conducted testing different lenses on their 
ability to block blue light (Figure 1). The amber glasses chosen for this study were selected for 
their superior ability to block blue light from entering the eye, blocking most of wavelengths the 
typically stimulate neural pathways connected to the SCN (<550 nm), while simultaneously 
allowing transmittance of other wavelengths (Esaki et al., 2016)(Figure 1). Grey lenses were 
chosen for the control condition to account for any effect on target metrics of merely wearing the 
glasses. Additionally, the grey lenses do not preferentially block short, blue wavelengths from 
entering the eye.  
Procedures and Design  
Participants in this study completed a 14-day balanced crossover design, in which each 
participant received the hypothesized active condition—amber glasses—as well as the control 
condition—grey glasses. This experiment consisted of six distinct phases over 14 days: Baseline 
(Day 0-3), Glasses Phase I (Day 4-6), Sleep Lab I (Day 7), Washout Phase (Day 8-10), Glasses 
Phase II (Day 11-13), and Sleep Lab II (Day 14). In each phase, participants were under distinct 
conditions and be administered distinct surveys (Figure 2). Participants responded to flyers and 
website advertisements and first completed a phone screen questionnaire with study staff to 
determine eligibility. Eligible participants then met with study staff to enroll, which started the 
baseline phase (Days 0-3). At enrollment, staff explained the details of the study and required 
participants to review consent documents. Consenting participants completed a demographics 
form, LSEQ, and PANAS; participants also reported the usual times they fall asleep and wake 
AMBER GLASSES, SLEEP, & AFFECT 
 16 
up. Participants were also given equipment (i.e., GENEActiv watch and glasses) and provided 
with information on proper use. The GENEActiv watches were worn by participants for all 14 
days of the study, but the glasses were worn by participants on only designated phases of the 
study. Participants completed two rounds of daily measures of sleep and mood (i.e., LSEQ, 
PANAS) each day—once in the morning and once in the evening. Participants also wore the 
GENEActiv watch and reported times they fell asleep and woke up for the remainder of the 
baseline phase. 
 During Glasses Phase I (Days 4-6), participants wore the pair of glasses to which they 
were first randomly assigned (i.e., amber or placebo control). Participants were instructed to put 
the glasses on three hours prior to their desired sleep onset time and to send a photograph of 
themselves wearing the glasses to the study coordinator to confirm protocol compliance. 
Participants continued to fill out daily measures of sleep and mood.  
 For the Sleep Lab I phase (Day 7), participants reported to the sleep laboratory 5 hours 
prior to their average sleep onset time. Participants slept in the laboratory overnight, spending 
roughly 12 hours in the sleep laboratory. Participants completed the evening daily measures of 
sleep and mood as usual. Participants were instructed to wear the glasses worn for the preceding 
three days three hours prior to sleep onset time. Participants wore the WatchPAT 300 while in 
the sleep laboratory. Participants left the sleep laboratory in the morning and begin the next 
phase of the study. 
 The Washout Phase (Day 8-10) required participants to follow similar protocol to the 
Baseline Phase. During this phase, participants completed measures on sleep, mood, and somatic 
complaints twice daily. Participants also continued to wear the GENEActiv watches, but did not 
wear the glasses. During Glasses Phase II (Dap 11-13), participants repeated the same protocol 
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as from Glasses Phase I except they switched their glasses color condition (i.e., participants who 
wore amber glasses during Glasses Phase I wore grey glasses during Glasses Phase II). During 
Sleep Lab II (Day 14), participants followed the same protocol as in Sleep Phase I except that 
they continued to wear the second shade of glasses. After Sleep Phase II, participants returned all 
their materials, were debriefed, and received their compensation. 
Data Analytic Plan 
 Data Rearrangement and Manipulation. Data were rearranged to allow for longitudinal 
analyses that are dependent on long format data. Random missing values were ignored in linear 
mixed effects regression (LMER). Participants with random missing values were excluded from 
t-test analyses.  
Preliminary Analyses. Preliminary analyses characterized the data and checked 
assumptions of kurtosis and skew. This included determining demographic information about 
age and gender of the participants, as well as identifying missing data.   
Linear Mixed-Effects Regression Analyses. Linear mixed-effects regression models for 
repeated measures were used to examine within-person change imparted by the amber glasses 
active condition on several outcome variables. The outcome variables on which this type of 
analysis was conducted were outcome variables measured everyday (e.g. PANAS negative and 
positive affect; GENEActiv sleep duration, efficiency; LSEQ sleep subscales) rather than only 
on sleep lab days. Linear mixed-effect modeling is preferable over other repeated measures 
analyses for these data as it accounts for natural within-person differences in baseline sleep 
behavior and mood, as outcome measures are nested within individuals before being compared 
across groups. Analyses were completed with the nlme package in R (Long, 2012). The models 
allowed for random intercepts and random slopes, as baseline measurement and rate of change of 
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each outcome variable were likely to vary between participants. The models tested for the fixed 
effects of day, condition, and day*condition on each outcome variable. As random effects for 
each model, we only had intercepts for subjects, as detecting the random effects of other 
variables required more power than we had given our small participants pool. P-values for each 
beta estimate were obtained by converting from the given t in the output. The chi-square values 
and p-values for each model were obtained through model likelihood ratio tests of the full 
models with the effect against the respective null models.  
T-Test and Cohen’s d Analyses. Paired-samples t-tests were used to examine the within-
person differences between the control grey glasses condition and the active amber glasses 
condition for all outcome variables measured only on the two sleep lab days (e.g., WatchPAT 
sleep duration, sleep latency, REM latency, number wakes, mean pulse, and mean oxygen 
saturation; PSQI sleep quality, duration, and latency). Participants who did not have data for both 
sleep lab phases were excluded from these analyses. As the sample size was low, Cohen’s d 
effect sizes were computed to accompany each t-test to provide more information about the 
effect of the condition on each outcome variable.  
 Aim 1. The first aim of this study was to evaluate the effects of amber glasses on key 
outcome measures of sleep: quality, duration, efficiency, and latency. As data from the 
WatchPAT 300 and PSQI were collected on only two occasions—once in the active condition 
and once in the control condition—t-tests evaluated group mean differences in the summary 
statistics. As the GENEActiv, LSEQ, and self-report sleep duration data were hierarchical in 
structure and longitudinal, linear mixed-effects regression models were used to test within-
person change as a result of the amber glasses.  
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We hypothesized that participants in the amber glasses condition would show 
significantly better quality of sleep based on subjective report (e.g., LSEQ, PSQI). We also 
predict that participants in the amber glasses condition will show longer sleep duration (e.g., 
GENEActiv, PSQI, daily self-report, WatchPAT), shorter sleep latency (e.g., WatchPAT, PSQI, 
LSEQ), and greater sleep efficiency (e.g., GENEActiv). We did not have hypothesized 
expectations for the effects of amber glasses on other criteria measured by the WatchPAT 300.  
Aim 2. The second aim of this study was to evaluate the effects of amber glasses on key 
outcome measures of positive and negative affect as measured by the PANAS. Affect measures 
were evaluated on multiple occasions before and after participants received the amber glasses 
intervention. As data from the affect measures were hierarchical in structure and longitudinal, 
linear mixed-effects regression models were used to test within-person change as a result of the 
amber glasses. We hypothesized that the amber condition will show significantly more positive 
affect, and significantly lower negative affect compared to baseline, and that those in the grey 
glasses control condition would not show such benefits.   
 Exploratory Aims. Dimensions of sleep are often difficult to measure, and results often 
differ due to both varying method and time of day of measurement (Meltzer, 2020). As this study 
includes a wide variety of methods to study sleep constructs, an exploratory aim of this study 
was to evaluate the agreement between subjective (LSEQ and PSQI) and objective (GENEActiv 
and WatchPAT) measures of sleep across duration, quality, and latency constructs. Agreement 
was also evaluated between the same measure of sleep quality and latency (PSQI) administered 
at two different times during the day. Correlation analyses quantified agreement.  
Results 
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A total of 15 participants, 10 males and 5 females from age 18 to 47 (M=27.07, 
SD=7.17), enrolled in the study who met inclusion and exclusion criteria. These 15 participants 
each completed amber glasses intervention, a control grey glasses condition, and baseline phase, 
and a washout phase. Every day during the 14-day study, these participants completed daily 
surveys of mood and sleep, and wore GENEActiv watches that monitored sleep. Twice during 
the study, at the end of each glasses phase, the 15 participants slept in the sleep laboratory, where 
they completed additional surveys and objective monitoring of sleep by WatchPAT 300 devices. 
Descriptive statistics for all of the predictor and outcome variables are listed in Table 1. As the 
PANAS and PSQI surveys were given twice per day—one in the morning and once at night—
AM and PM scores were calculated separately for each participant. 
Sleep Quality  
The two measures of sleep quality included in this study were two daily estimates from 
the LSEQ (BFW and QOS subscales) and a weekly sleep quality rating from the PSQI. The 
effect of day, condition, and a day by condition interaction on LSEQ Behavior Following 
Waking (BFW) POMP scores was determined using linear mixed-effects regression models 
(χ2(1)=3.74, p=0.81). The intercept of predicted LSEQ Behavior Following Waking (BFW) 
POMP scores varied between participants, SD= .05, ICC=.34. Figure 3 shows the spaghetti plots 
of LSEQ BFW POMP scores by condition with trend lines for each participant as linear 
regressions, and Figure 4 shows the spaghetti plots of LSEQ BFW POMP scores by condition 
showing the high variability within participant. Table 2 displays the regression weights. The 
intercept was significantly different than zero, indicating that the average participant’s initial 
LSEQ BFW POMP score was 51% of the maximum possible score. No significant effects from 
day, condition, or day*condition on LSEQ BFW POMP scores were found.  
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The effect of day, condition, and a day by condition interaction on LSEQ Quality of 
Sleep (QOS) POMP scores was also determined using linear mixed-effects regression models 
(χ2(1)=17.68, p=0.01). The intercept of predicted LSEQ Quality of Sleep (QOS) POMP scores 
varied between participants, SD= .06, ICC=.30. Figure 3 shows the spaghetti plots of LSEQ QOS 
POMP scores by condition with trend lines for each participant as linear regressions, and Figure 
4 shows the spaghetti plots of LSEQ QOS POMP scores by condition showing the spread of data 
by participant. Beta weights are displayed in Table 3. Intercept was significantly different than 
zero, indicating that the average participant’s LSEQ QOS POMP score was 59% of the 
maximum possible score. While allowing intercepts and slopes to vary randomly, there was no 
significant effect of day on LSEQ QOS POMP scores. There was a significant effect of the 
washout phase condition on LSEQ QOS POMP scores, predicting a 92% initial decrease LSEQ 
QOS POMP score upon starting the washout phase. There was also a significant effect of the day 
and washout phase interaction, which indicates that participant’s LSEQ QOS POMP scores 
increased 13% each day they spend in the washout phase condition. 
The effect of condition on weekly ratings of sleep quality from PSQI was determined 
using paired-sample t-tests (Table 4). PSQI sleep quality ratings in the morning and evening 
were expected to agree, but these constructs were separated to ensure accuracy of analyses. The 
paired-sample t-tests for both AM and PM PSQI sleep quality ratings were not significant 
(Figure 5). However, the Cohen’s d was small and positive, meaning PSQI sleep quality scores 
were higher for those in the grey condition than the amber condition. As higher scores on the 
sleep quality PSQI item indicate worse sleep quality, those in the amber condition had slightly 
better sleep quality than those in the grey glasses condition, though this difference was not 
significant.  
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Sleep Duration 
The three measures of sleep duration included in this study were a daily estimate from 
GENEActiv, a weekly objective sleep duration estimate from the WatchPAT, and a weekly self-
report sleep duration estimate from the PSQI. The effect of day, condition, and a day by 
condition interaction on GENEActiv sleep duration was determined using linear mixed-effects 
regression models (χ2(1)=11.49, p=0.12). The intercept of predicted GENEActiv sleep duration 
varied between participants, SD= 1.30, ICC=.130. Figure 6 shows the spaghetti plots of 
GENEActiv sleep duration by condition with trend lines for each participant as linear 
regressions, and Figure 7 shows the spaghetti plots of GENEActiv sleep duration by condition 
showing the spread of data by participant. Beta weights are displayed in Table 5. The intercept 
was significantly different than zero, indicating that for the average participant, initial 
GENEActiv sleep duration was 10.46 hours. While allowing intercepts and slopes to vary 
randomly, there was a significant effect of day on GENEActiv sleep duration, there was a 
significant effect of amber glasses on GENEActiv sleep duration, predicting a 1.76-hour initial 
decrease in sleep duration. There were no significant effects of day or the day by condition 
interaction on sleep duration as measured by the GENEActiv.  
The effect of condition on weekly ratings of sleep duration from the WatchPAT and 
PSQI were determined using paired-sample t-tests (Table 4).  The paired-sample t-test for 
WatchPAT sleep duration was approaching significance (Figure 8). The Cohen’s d value was 
large and negative, indicating that participants slept longer when in the amber glasses condition 
than when they were in the grey glasses control condition. PSQI sleep duration ratings were 
collected in the morning and evening and expected to agree; all participants responded to the 
PSQI sleep duration item in the morning, but many skipped this item in the afternoon 
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administration. Therefore, only PSQI_AM ratings of sleep duration were analyzed. The paired-
sample t-test for PSQI_AM sleep duration was not significant (Figure 8). The Cohen’s d value 
was small and negative, indicating that participants slept marginally longer when in the amber 
glasses condition than when they were in the grey glasses control condition based on self-ratings.  
Sleep Latency 
The three measures of sleep latency included in this study were a daily ease of getting to 
sleep rating from the GTS subscale of the LSEQ, a weekly objective sleep latency estimate from 
the WatchPAT, and a weekly self-report sleep latency estimate from the PSQI. The effect of day, 
condition, and a day by condition interaction on LSEQ Getting to Sleep (GTS) POMP scores was 
determined using linear mixed-effects regression models (χ2(1)=12.50, p=0.09). The intercept of 
predicted LSEQ Getting to Sleep (GTS) POMP scores varied between participants, SD= .08, 
ICC=.42. Figure 9 shows the spaghetti plots of LSEQ GTS POMP scores by condition with trend 
lines for each participant as linear regressions, and Figure 10 shows the spaghetti plots of LSEQ 
GTS POMP scores by condition showing the spread of data by participant. Beta weights are 
displayed in Table 6. The intercept was significantly different than zero, indicating that the 
average participant’s initial LSEQ GTS POMP score was 64% of the maximum possible score. 
There was a significant effect of the washout phase on GENEActiv sleep duration, predicting a 
57% initial decrease from baseline in LSEQ GTS POMP scores. Lower POMP scores on the 
LSEQ GTS sub scale indicate more trouble getting to sleep. There was no significant effect of 
day alone on LSEQ GTS POMP scores. However, there was a significant effect of the day and 
washout phase interaction on LSEQ GTS POMP score, which indicates that participant’s LSEQ 
GTS POMP score increased 8% each day they spent in the washout phase, indicating increase in 
the ease of getting to sleep. 
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The effect of condition on weekly ratings of sleep latency from both the WatchPAT and 
the PSQI were determined using paired-sample t-tests (Table 4). The paired-sample t-test for 
WatchPAT sleep latency was insignificant (Figure 11). The Cohen’s d of -.11 indicates that the 
amber glasses intervention had little to no differential effect on sleep latency of 
participants. Sleep quality ratings from the PSQI in the morning and evening were expected to 
agree, but these constructs were separated to ensure accuracy of analyses and reporting. The 
paired-sample t-tests for AM and PM PSQI sleep latency ratings were both insignificant (Figure 
11). The Cohen’s d effect sizes were positive for both AM and PM PSQI measurements; the 
Cohen’s d was small for the AM PSQI self-report sleep latency and medium for PM PSQI self-
report sleep latency. This indicates that participants had shorter sleep latency when under the 
amber glasses condition than under the grey glasses condition, though this difference was small 
and was not significant.  
Sleep Efficiency 
GENEActiv devices yielded the daily measure of sleep efficiency in this study. The effect 
of day, condition, and a day by condition interaction on GENEActiv sleep efficiency was 
determined using linear mixed-effects regression models (χ2(1)=15.24, p=0.03). The intercept of 
predicted GENEActiv sleep efficiency varied between participants, SD= .07, ICC=.162. Figure 
12 shows the spaghetti plots of GENEActiv sleep efficiency by condition with trend lines for 
each participant as linear regressions, and Figure 13 shows the spaghetti plots of GENEActiv 
sleep efficiency by condition showing the spread of data by participant. Beta weights are 
displayed in Table 7. The intercept was significantly different than zero, indicating that the 
average participant’s initial GENEActiv sleep efficiency was 64%. No significant effects from 
day, condition, or the day by condition interaction on GENEActiv sleep efficiency were found.  
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Other Sleep Constructs 
The weekly measurements from the WatchPAT on both sleep lab phases yielded 
summary statistics for several other sleep-related constructs: REM latency, number of wakes 
during the night, mean pulse, and mean blood oxygen saturation (Table 4). The paired-sample t-
test for REM latency was insignificant (Figure 14). The Cohen’s d for this t-test was medium and 
positive, indicating that when in the amber glasses condition, participants had a shorter REM 
latency than when in the grey glasses condition. The paired-sample t-test for number of wakes 
during sleep was insignificant (Figure 14). The Cohen’s d is for this t-test was medium and 
negative, indicating that those in the grey glasses control condition woke up less during the night 
than when in the amber glasses condition. The paired-sample t-test for mean pulse during sleep 
was insignificant (Figure 14). The Cohen’s d of .09 for this t-test indicates that the intervention 
had no effect on mean pulse of participants over the course of a night’s sleep regardless of their 
assigned condition. The paired-sample t-test for mean blood oxygen saturation was insignificant 
(Figure 14). The Cohen’s d for this t-test was small and negative, indicating that participants had 
slightly higher mean oxygen saturation in their blood during sleep when they were in the amber 
glasses condition than when they were in the grey glasses condition.  
Positive Affect 
The positive affect subscale of the PANAS was used as the daily measurement of positive 
affect in this study. Affect ratings from the PANAS in the morning and evening were not 
expected to agree, as affect generally changes throughout the day (Clark et al., 1989); therefore, 
these constructs were separated to ensure accuracy of analyses and reporting. PANAS positive 
affect subscale scores were converted to percentage of maximum possible (POMP) scores, with 
higher scores indicating more positive affect.  
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The intercept of predicted morning ratings of positive affect from the PANAS varied 
between participants, SD= .09, ICC=.57. Figure 15 shows the spaghetti plots of PANAS AM 
positive affect by condition with trend lines for each participant as linear regressions, and Figure 
16 shows the spaghetti plots of PANAS AM positive affect by condition showing the spread of 
data by participant. Beta weights are displayed in Table 8, χ2(1)=13.81, p=0.05. Intercept was 
significantly different than zero, indicating that the average participant’s PANAS AM positive 
affect score was 38% of the maximum score possible. Higher scores of the PANAS positive 
affect subscale indicate more positive affect. There was no significant effect of day, condition, or 
day*condition on AM ratings of positive affect.  
The intercept of predicted evening ratings of positive affect from the PANAS varied 
between participants, SD= .08, ICC=.57.  Figure 15 shows the spaghetti plots of PANAS PM 
positive affect by condition with trend lines for each participant as linear regressions, and Figure 
16 shows the spaghetti plots of PANAS PM positive affect by condition showing the spread of 
data by participant. Beta weights are displayed in Table 9, χ2(1)=27.36, p=0.0003. The intercept 
was significantly different than zero, indicating that the average participant’s PANAS PM 
positive affect score was 38% of the maximum score possible. There was no significant effect of 
day or day*condition on evening ratings of PANAS positive affect. However, there were 
significant effects of amber glasses on evening ratings of PANAS positive affect, predicting an 
8% initial increase in PANAS positive affect POMP score upon starting the amber glasses 
condition.  
Negative Affect 
The negative affect subscale of the PANAS was used as the daily measurement of 
negative affect in this study. Affect ratings from the PANAS in the morning and evening were 
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not expected to agree, as affect generally changes throughout the day (Clark et al., 1989); 
therefore, these constructs were separated to ensure accuracy of analyses and reporting. PANAS 
negative affect subscale scores were converted to percentage of maximum possible (POMP) 
scores, with higher scores indicating more negative affect.  
The intercept of predicted morning ratings of negative affect from the PANAS varied 
between participants, SD= .01, ICC=.33. Figure 15 shows the spaghetti plots of PANAS AM 
negative affect by condition with trend lines for each participant as linear regressions, and Figure 
16 shows the spaghetti plots of PANAS AM negative affect by condition showing the spread of 
data by participant. Beta weights are displayed in Table 10, χ2(1)=11.04, p=0.14. The intercept 
was significantly different than zero, indicating that the average participant’s PANAS AM 
negative affect score was 25% of the maximum score possible. While allowing intercepts and 
slopes to vary randomly, there was a significant effect of day on PANAS AM negative affect, 
predicting an 1% decrease in negative affect each day the participant is in any condition (amber, 
grey, or washout) compared to baseline. Additionally, there was a significant effect of amber 
glasses on AM negative affect, predicting a 3% initial decrease in negative affect upon starting 
the amber glasses condition. There was also a significant effect of grey glasses on AM negative 
affect, predicting a 2% initial decrease in negative affect upon starting the amber glasses 
condition. Lastly, there were significant effects of the day and amber glasses interaction, the day 
and grey glasses interaction, and the day and washout phase interaction, which indicate that 
participant’s AM negative affect increased 1%, 1%, and 2% of the maximum possible score, 
respectively, each day they spent in each condition. 
The intercept of predicted evening ratings of negative affect from the PANAS varied 
between participants, SD= .02, ICC=.32. Figure 15 shows the spaghetti plots of PANAS PM 
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negative affect by condition with trend lines for each participant as linear regressions, and Figure 
16 shows the spaghetti plots of PANAS PM negative affect by condition showing the spread of 
data by participant. Beta weights are displayed in Table 11, χ2(1)=2.07, p=0.96. Intercept was 
significantly different than zero, indicating that the average participant’s PANAS PM negative 
affect score was 23% of the maximum score possible. Higher scores of the PANAS negative 
affect subscale indicate more negative affect. There was no significant effect of day, condition, 
or day*condition on PM ratings of negative affect.  
Sleep Measures Agreement 
To analyze the agreement between different measurements of sleep duration, sleep 
quality, and sleep latency, Pearson r correlations were calculated between the multiple measures 
of these constructs; see Figure 17. Sleep duration measures all had a small to large positive 
correlations with one another (e.g., r=.26 between GENEActiv and WatchPAT), which indicates 
good agreement overall between these measures. For the sleep quality construct, SQ_PSQI_AM 
and SQ_PSQI_PM items were reverse scored so that higher scores indicate more sleep quality. 
Therefore, agreement amongst sleep quality measures is indicated by positive correlations. For 
the sleep quality measures, there are disagreements not only between the LSEQ and PSQI 
measurements of sleep quality (e.g., r= -.13 between LSEQ_QOS and PSQI_PM), but there is 
also disagreement within different subscales of the LSEQ (e.g., r=.02 between LSEQ_BFW and 
LSEQ_QOS) and between the PSQI measured at different times of day (e.g., PSQI_AM 
correlates r= .22 with LSEQ_BFW but PSQI_PM correlates r= -.1 with LSEQ_BFW).  This 
indicates large discrepancies between different self-report measures of sleep quality, and that 
self-rated sleep quality is sensitive to time of day when reporting. For the sleep latency construct, 
SL_LSEQ_GTS items are normally scored such that higher scores indicate greater ease in falling 
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asleep (low sleep latency), which is the opposite of the other sleep latency estimates. Therefore, 
the SL_LSEQ_GTS were reverse scored so that lower scores indicate lower sleep latency. With 
these adjustments, agreement between the sleep latency measures would be indicated by positive 
correlations. The SL_LSEQ_GTS had small negative correlations with the other sleep latency 
(e.g., r=-.21 between LSEQ_GTS (self-report) and WatchPAT (objective)), indicating that the 
LSEQ measurement of sleep latency does not agree with the other sleep latency measures. The 
PSQI and WatchPAT measures of sleep latency had medium positive correlations, showing 
strong agreement between these measures (e.g., r=.45 between WatchPAT (objective) and 
PSQI_AM (self-report)). Notably, the PSQI_AM and PSQI_PM measures of sleep latency had 
strong agreement (r=.97), indicating similar self-report estimates of sleep latency regardless of 
the time of day when participants were measured.  
Discussion 
This study aimed to elucidate the effect of an amber glasses intervention on sleep and 
affect. This is one of the first studies to test the effect of an amber glasses intervention on affect 
and sleep using both self-report and objective measures. We hypothesized that participants in the 
amber glasses condition would show significantly higher sleep quality, longer sleep duration, 
shorter sleep latency and higher sleep efficiency both compared to baseline and compared to the 
grey glasses condition.  All of these changes are desirable functionally, and would increase the 
mental and physical health of participants. We did not have specific hypotheses about the other 
sleep constructs measured in this study (e.g, REM latency, number of wakes, mean pulse, mean 
oxygen saturation). If our hypothesis were true, then we would expect the amber glasses to 
predict an immediate and sustained increase sleep quality, duration, and efficiency, as well as an 
immediate and sustained decrease in sleep latency. This would be indicated by a significant 
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amber glasses condition effect and by a significant amber condition by day interaction effect on 
each sleep outcome variable. Our results on sleep quality, sleep duration, sleep efficiency, and 
sleep latency generally do not support our hypotheses. No significant group differences were 
found amongst the other sleep constructs examined. However, some results are promising, and 
some of the null-results may be attributed to methodological shortcomings and analytical 
difficulties.  
We also hypothesized that participants in the amber glasses condition would show 
significantly more positive affect and show significantly lower negative affect compared to 
baseline. Both of these changes are desirable functionally. We also hypothesized that those in the 
grey glasses condition would not show such benefits. If our hypothesis were true, then we would 
expect the amber glasses to predict an immediate and sustained increase positive affect, as well 
as an immediate and sustained decrease in negative affect. This would be indicated by a 
significant amber glasses condition effect and by a significant amber condition by day interaction 
effect on each outcome variable. Some aspects of our results do support our hypotheses, and 
novel differences were found between the effect of amber glasses on positive and negative affect 
alone and dependent on time of day. Specifically, we found that the effect of amber glasses was 
strongest for positive affect in the evening, but not in the morning. We also detected small, but 
non-exclusive, effects of amber glasses on morning negative affect. 
The results from the analyses of the various sleep quality measures in the present study 
do not strongly support our hypotheses. Neither amber glasses nor the amber glasses by day 
interaction predicted significant increases in score for either the behavior following waking or 
the quality of sleep subscales of the LSEQ. The paired-sample t-tests for sleep quality measures 
were also non-significant, and the small effect sizes corresponding to these t-tests indicated only 
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slightly better sleep quality in amber glasses condition than the grey glasses condition. No 
adverse effects of amber glasses were found. Our results disagree with that of other studies, 
which indicated that all or many participants wearing amber glasses reported significantly higher 
sleep quality than controls (Burkhart & Phelps, 2009; Esaki et al., 2017).  
The results of the analyses for sleep duration and sleep efficiency do not support our 
hypotheses, but also should be interpreted with hesitation due to analytical and methodological 
difficulties. Amber glasses significantly predicted an initial decrease in GENEActiv sleep 
duration, but the effect of the day by amber glasses interaction was not significant. This indicates 
that amber glasses had a strong immediate effect on participants by decreasing sleep duration, 
and that this effect did not change over the days in the amber glasses condition. Importantly, no 
other condition or day by condition interaction was significant, meaning the amber glasses 
exclusively had this adverse effect on participants. This effect is troublesome, as it may indicate 
that the amber glasses had a specific deleterious effect on participants. Dually, this effect is 
troublesome as it differs from the results of the t-tests in the present study, which indicated that 
on self-report and objective sleep duration measures, participants slept longer in the amber 
glasses condition. However, there is some literature that shows that similar blue-blocking lenses 
do reduce sleep duration, though non-significantly, relative to control lenses (Landers et al., 
2009). The analyses for the GENEActiv sleep efficiency data indicated that there was no 
significant immediate or lasting effect amber glasses. GENEActiv data is difficult to analyze, as 
it difficult to differentiate extreme data from data resulting from participant non-compliance (i.e., 
participants forgetting to wear the device). Based off of the large spread in results of both the 
GENEActiv sleep duration (Figure 7) and sleep efficiency (Figure 13) summary statistics, it is 
clear that these summary statistics were influenced by participant non-compliance. GENEActiv 
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sleep duration data was modified before analyses were run to adjust for such non-compliance as 
much as possible, but some data points that are a result of non-compliance may have been left in 
the dataset because they could not reliably be differentiated from true scores. GENEActiv sleep 
efficiency data could not be equivalently modified. Due to difficulties in data cleaning for 
GENEActiv data, the results of the linear mixed effects regressions for GENEActiv sleep 
duration and efficiency should be interpreted with hesitation.  
The results from the analyses of the various sleep latency measures in the present study 
do not strongly support our hypotheses. There were no significant effects of amber glasses or the 
amber glasses by day interaction on the getting to sleep subscale of the LSEQ. The paired-
sample t-tests also found no significant group differences for sleep latency between the amber 
glasses and grey glasses condition. These findings are in contrast to other literature that found 
amber glasses to be effective at pushing sleep circadian rhythms and sleep onset forward, which 
would decrease sleep latency (Esaki et al., 2016). The washout phase and grey glasses condition 
did, however, predict significant—or approaching significant—decreases in the ease of getting to 
sleep. The adverse effects conferred on the participants by the grey glasses and washout phase 
was unexpected and troublesome. It is possible, though, that these adverse effects are driven by a 
loss of benefit of the amber glasses, or that they are Type 1 error.  
Findings from the analyses of positive and negative affect did not fully support our 
original hypotheses, but do provide novel insight about the effectiveness of amber glasses on 
affect at different times of day. Amber glasses did not predict any changes in positive affect in 
the morning, but did predict an initial significant and notable increase in positive affect in the 
evening. Dually, no other condition predicted significant changes in positive affect in the 
evening. Amber glasses did not predict changes in evening negative affect, but did predict a 
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small significant decrease in negative affect in the morning. However, grey glasses and the 
washout phase also predicted similar decreases in morning negative affect; therefore, this effect 
may not be exclusive to amber glasses. One explanation is that baseline morning negative affect 
was randomly higher than typical (Figure 16), thus resulting in decreases in negative affect over 
the rest of the study and Type 1 error. Regardless, the low betas associated with these significant 
findings indicate only minimal decreases in participants’ negative affect, which is not clinically 
meaningful.  
In all, these findings provide evidence in support of our positive affect hypothesis, 
provide some preliminary support for our negative affect hypothesis, and provide a novel finding 
about the particular effectiveness of amber glasses on evening positive affect. These results agree 
with findings from other amber glasses studies (Burkhart & Phelps, 2009). Our results 
corroborate and could be explained by findings that positive affect, but not negative affect, varies 
diurnally, indicating that positive affect is more directly controlled by circadian rhythms, which 
amber glasses manipulate (Clark et al., 1989). Amber glasses have been found to significantly 
decrease negative mood in other studies, however, this effect was found in participants with 
mood disorders rather than participants without any DSM-5 diagnosis (Glickman et al., 2006; 
Henriksen et al., 2016). 
In all, small sample size, large interpersonal variation, and some participant 
noncompliance limit the ability to draw conclusions from this feasibility study. Sleep and mood 
vary diurnally, however, the assumptions of the mixed-effect models used were linear growth 
over time. Many of the models run to predict each of the outcome variables via linear mixed-
effects regression were not significantly superior to their respective null models. This is may be 
evidence that the assumptions of linear growth inherent to mixed-effects models may not fit the 
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data well. Autoregressive integrated moving average (ARIMA) is an example of a type of 
analysis that may be better suited to data of this kind, as ARIMA better accounts for the 
sinusoidal or curvilinear variation of many of the outcome variables. ARIMA requires at least 30 
repeated measures of each outcome variable, so the methodology would need to be altered to 
allow such analyses. Ecological momentary assessment could enable more frequent assessment 
(Trull & Ebner-Priemer, 2013), as well as allow examination of known circadian variation in the 
outcome variables through ARIMA (Glickman et al., 2006; Henriksen et al., 2016). Future 
studies should use these modern methodologies to examine the effect of amber glasses on similar 
outcome variables. Dually, the lack of model fit may have been due to the small sample size, 
which limited the power to detect random between-participant variation in the outcome 
measures. As seen in the various spaghetti plots, there was a lot of between-participant variation, 
and if there were more power, the models could more accurately parse between random effects 
and the fixed effect of the intervention. Our small sample size may have also increased 
likelihood of Type II error. Future studies should aim to recruit more participants to negate such 
power issues.  
Participant non-compliance surrounding daily use of the GENEActiv devices limited 
conclusions we could draw from such data. Though objective measures of sleep do have the 
potential to help sleep researchers overcome barriers related to self-report measurement, current 
limitations of GENEActiv use and analytic software (e.g. Macros sheet) make it an unreliable 
tool for daily objective sleep measurement. Future studies should aim to find more sophisticated 
methods to extract summary statistics from GENEActiv data, find ways to enhance participant 
compliance for these devices, and find new methods to objectively measure sleep over a 
longitudinal study.  
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To conclude, though the results of this study did not strongly support our hypotheses that 
amber glasses would increase sleep quality, duration, and efficiency and decrease sleep latency, 
our results did show both preliminary evidence that amber glasses could help decrease negative 
affect and strong evidence that amber glasses could increase positive affect, especially in the 
evening. Amber glasses have been shown in many studies to be an effective adjunct treatment for 
mood disorders, and this study provides more evidence that amber glasses may be helpful for 
individuals with sleep and mood concerns below the clinical level as well. Future studies with 
larger samples sizes, as well as more advanced methodology and analytical techniques, will help 
illuminate the true effect of amber glasses interventions on sleep and affect, and will help 
advance amber glasses as a viable treatment for those with sleep and mood concerns.  
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Figure 1. Light transmittance for amber lenses used in this study. Wavelengths of light below 
approximately 550 nm act on the retinal pathway that modulates the SCN and subsequent 
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Figure 2. Example study timeline for a participant who received the amber glasses condition 
first, followed by the control grey glasses condition.  
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Table 1.  
Descriptive statistics for all variables used 




Condition 210 2.5 1.05 1 4 3 0 -1.22 0.07 
Predictor 
(Time) 
Day 210 2.21 1.66 0 5 5 0.03 -1.39 0.11 
Sleep 
Duration 
WatchPAT 30 372 46.54 214 453 239 -1.13 2.28 8.5 
GENEActiv 191 438.77 224.1 137 1440 1303 2.92 9.29 16.22 
PSQI_AM 30 7.1 1.19 3.71 9 5.29 -0.86 0.58 0.22 
Sleep Quality PSQI AM 21 1.71 0.72 1 3 2 0.43 -1.09 0.16 
PSQI PM 28 2.04 0.51 1 3 2 0.07 0.71 0.1 
LSEQ_QOS_POMP 205 0.53 0.16 0.08 1 0.92 0.22 0.31 0.01 
LSEQ_BFW_POMP 202 0.48 0.14 0.08 0.8 0.72 -0.26 -0.12 0.01 
Sleep 
Latency 
LSEQ_GTS_POMP 206 0.57 0.14 0.27 0.99 0.71 0.67 0.18 0.01 
WatchPAT 30 30.5 14.64 10 65 55 0.71 -0.73 2.67 
PSQI_AM 29 17.21 15.91 5 90 85 3.25 12.23 2.95 
PSQI_PM 27 19.41 27.20 5 150 145 4.07 16.71 5.23 
Sleep 
Efficiency 




REM latency 29 101.9 57.17 33 213 180 0.79 -0.91 10.62 
Number wakes 30 6.07 3.14 2 14 12 0.46 -0.31 0.57 
Mean pulse 30 57.4 9.17 42 79 37 0.79 0.03 1.67 




AM POMP 208 0.35 0.12 0.2 0.8 0.6 0.74 0.33 0.01 




AM POMP 208 0.22 0.03 0.2 0.36 0.16 2.49 7.14 0 
PM POMP 199 0.22 0.04 0.2 0.48 0.28 3.57 16.47 0 
 
Note: POMP = Percent of Maximum Possible; PSQI = Pittsburgh Sleep Quality Index; PANAS = Positive and 
Negative Affective Schedule; LSEQ = Leeds Sleep Evaluation Questionnaire; GTS= Getting to Sleep; QOS= 








Figure 3. Spaghetti plots for sleep quality outcome variables by condition: LSEQ_BFW (Behavior Following 
Wakening) and LSEQ_QOS (Quality of Sleep). Trend lines are regressions for each participant showing changes 
in the outcome variable over the days in each condition. Colors represent the glasses conditions, the first panel 
represents baseline, and the fourth panel represents the washout phase. For LSEQ_BFW, there were no significant 
effects of day, condition, or the day by condition interaction. For LSEQ_QOS, there were significant effects of 
the washout phase, and the washout by day interaction, in that the washout condition caused significant 
immediate decrease in quality of sleep, but that participants QOS scores increased back to baseline levels as days 









 .  
Figure 4. Spaghetti plots for sleep quality outcome variables by condition: LSEQ_BFW (Behavior Following 
Wakening) and LSEQ_QOS (Quality of Sleep). Trend lines connect the data points for each participant showing 
changes in the outcome variable over the days in each condition. Colors represent each participant. Panels 0 through 
3 represent the baseline, amber glasses, grey glasses, and washout conditions, respectively. This shows the high 
amount of within-person variance across days and conditions. 
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Table 2.  
Beta Weights Predicting Sleep Quality as measured by the LSEQ BFW (Behavior Following 
Wakening) subscale 
      
Predictor  ß  SEß t df p ICC 
(Intercept) 0.51 0.05 10.11 202 <.00005 0.34 
Day  -0.01 0.02 -0.37 202 0.36  
Amber Glasses -0.00 0.07 -0.02 202 0.49  
Grey Glasses  -0.03 0.07 -0.38 202 0.35  
Washout  0.04 0.21 0.19 202 0.42  
Day*Amber Glasses 0.00 0.02 0.15 202 0.34  
Day*Grey Glasses     0.01 0.02 0.31 202 0.38  
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Table 3.  
Beta Weights Predicting Sleep Quality as measured by the LSEQ QOS (Quality of Sleep) 
subscale 
      
Predictor  ß  SEß t df p ICC 
(Intercept) 0.59 0.06 10.01 205 <.00005 0.30 
Day  -0.03 0.03 -1.29 205 0.10  
Amber Glasses -0.01 0.08 -0.13 205 0.45  
Grey Glasses  -0.01 0.08 -0.08 205 0.47  
Washout  -0.92 0.24 -3.75 205 0.0001  
Day*Amber Glasses 0.03 0.03 1.07 205 0.14  
Day*Grey Glasses     0.03 0.03 1.11 205 0.13  
Day*Washout 0.13 0.04 3.37 205  0.0004  
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Table 4.  
Paired samples t-test results for outcome variables measured only on Sleep Lab Phases 1 and 2. 
 M1 SD1 M2 SD2 t df p Cohen's d 
Sleep_duration_WatchPAT 384.27 32.07 359.73 56.00 1.60 14 0.131 -0.56 
REM_latency_WatchPAT 91.36 57.02 112.07 59.63 -1.00 13 0.334 0.37 
Number_wakes_WatchPAT 6.53 3.81 5.60 2.32 0.81 14 0.433 -0.31 
Mean_pulse_WatchPAT 57.00 9.66 57.80 8.98 -0.22 14 0.826 0.09 
Oxy_saturation_WatchPAT 95.80 0.94 95.67 1.29 0.30 14 0.769 -0.12 
Sleep_duration_PSQI_AM 7.22 0.96 6.98 1.41 0.56 14 0.58 -0.21 
PSQI_Sleep_Quality_AM 1.70 0.67 1.80 0.79 -0.26 9 0.798 0.14 
PSQI_Sleep_Quality_PM 2.00 0.41 2.08 0.49 -0.56 12 0.585 0.18 
Sleep_latency_WatchPAT 31.27 14.65 29.73 15.11 0.26 14 0.800 -0.11 
Sleep_latency_PSQI_AM 14.71 8.34 19.14 21.45 -0.70 13 0.494 0.28 
Sleep_latency_PSQI_PM 14.67 9.32 25.67 39.78 -0.95 11 0.363 0.40 
 
Note: Groups are indicated by subscripts. Group 1 is the amber glasses active condition, and group 2 is the grey 
glasses control condition, so positive values of d mean that the average was higher in the amber condition.  
  




Figure 5. Ridgeline plots of sleep quality measures by condition: PSQI sleep quality item measured in the morning 
and in the evening. The three red lines on each ridgeline plot indicate—from left to right—the first quartile, the 
median, and the third quartile. The sleep quality differences between the amber glasses and grey glasses groups were 
non-significant for both the PSQI_AM and PSQI_PM.  
 
  




Figure 6. Spaghetti plots for the sleep duration (in hours) outcome measure by condition: GENEActiv. Trend lines 
are regressions for each participant showing changes in the outcome variable over the days in each condition. Colors 
represent the glasses conditions, the first panel represents baseline, and the fourth panel represents the washout 
phase. For GENEActive measurements, sleep duration was filtered so values over 12 hours were excluded, as more 
extreme values of sleep duration indicate that participants neglected to put on the GENEActiv device. For the 
GENEActiv sleep duration outcome variable, there was a significant effect of the amber glasses condition, 
indicating an immediate but non-progressive decrease in sleep duration as a result of the amber glasses intervention.  
  




Figure 7. Spaghetti plots for sleep duration (in hours) outcome measure by condition: GENEActiv. Trend lines 
connect the data points for each participant showing changes in the outcome variable over the days in each 
condition. Colors represent each participant. Panels 0 through 3 represent the baseline, amber glasses, grey glasses, 
and washout conditions, respectively. Participants with sleep duration over 12 hours were filtered out before linear 
mixed effects regression analyses were conducted, as extreme values indicated participants not wearing the 
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Table 5.  
Beta Weights Predicting Sleep Duration as measured by GENEActiv 
      
Predictor  ß  SEß t df p ICC 
(Intercept) 6.76 .65 10.44 179 <.00005 .283 
Day  -0.08 0.27 -0.30 179 0.38  
Amber Glasses -1.76 0.83 -2.13 179 0.02  
Grey Glasses  -0.68 0.85 -0.80 179 0.21  
Washout  2.81 2.40 1.17 179 0.12  
Day*Amber Glasses 0.23 0.28 0.80 179 0.21  
Day*Grey Glasses     0.14 0.28 0.51 179 0.31  
Day*Washout -0.26 0.38 -0.71 179 0.24  
  
Note: Sleep duration was filtered so values over 12 hours were excluded, as more extreme values of sleep duration 
indicate that participants neglected to put on the GENEActiv device.  
  





Figure 8. Ridgeline plots of sleep duration (in hours) measured by WatchPAT and PSQI in the morning by 
condition. The three red lines on each ridgeline plot indicate—from left to right—the first quartile, the median, and 
the third quartile. The groups differences for sleep duration were approaching significance for the WatchPAT and 
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Figure 9. Spaghetti plots for sleep latency outcome variable by condition: LSEQ_GTS (Getting to Sleep). Trend 
lines are regressions for each participant showing changes in the outcome variable over the days in each condition. 
Colors represent the glasses conditions, the first panel represents baseline, and the fourth panel represents the 
washout phase. For LSEQ_GTS, there were significant effects of the washout condition, and the day by washout 
condition, in that the washout condition caused a significant and immediate decrease in ease of getting to sleep, and 
but the participants’ scores increased back to baseline levels as days in the washout phase passed.  
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Figure 10. Spaghetti plots for sleep latency outcome variable by condition: LSEQ_GTS (Getting to Sleep). Trend 
lines connect the data points for each participant showing changes in the outcome variable over the days in each 
condition. Colors represent each participant. Panels 0 through 3 represent the baseline, amber glasses, grey glasses, 
and washout conditions, respectively.   
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Table 6.  
Beta Weights Predicting Sleep Quality as measured by the LSEQ GTS (Getting to Sleep) 
subscale 
      
Predictor  ß  SEß t df p ICC 
(Intercept) 0.64 0.05 13.27 206 <.00005 0.42 
Day  -0.02 0.02 -1.22 206 0.11  
Amber Glasses -0.07 0.06 -1.08 206 0.14  
Grey Glasses  -0.10 0.06 -1.56 206 0.06  
Washout  -0.57 0.18 -3.03 206 0.001  
Day*Amber Glasses 0.02 0.02 1.15 206 0.13  
Day*Grey Glasses     0.03 0.02 1.35 206 0.09  
Day*Washout 0.08 0.03 2.70 206 0.004  
 
  






Figure 11. Ridgeline plots of sleep latency measured by WatchPAT, PSQI in morning, PSQI in evening by 
condition. The three red lines on each ridgeline plot indicate—from left to right—the first quartile, the median, and 
the third quartile. The groups differences in sleep latency were non-significant for WatchPAT, PSQI_AM, and 
PSQI_PM. These measurements took place on the same nights of sleep, and from these data, it is apparent that 
participants generally self-rated their sleep latency lower than what was measured objectively my the WatchPAT. 
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Figure 12. Spaghetti plots for GENEActiv sleep efficiency outcome variable by condition. Trend lines are 
regressions for each participant showing changes in the outcome variable over the days in each condition. Colors 
represent the glasses conditions, the first panel represents baseline, and the fourth panel represents the washout 
phase. For the GENEActiv sleep efficiency outcome variable, there were no significant effects of day, condition, or 
the day by condition interaction.  
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Figure 13. Spaghetti plots for GENEActiv sleep efficiency outcome variable by condition. Trend lines connect the 
data points for each participant showing changes in the outcome variable over the days in each condition. Colors 
represent each participant. Panels 0 through 3 represent the baseline, amber glasses, grey glasses, and washout 
conditions, respectively.   
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Table 7.  
Beta Weights Predicting Sleep Efficiency as measured by GENEActiv 
      
Predictor  ß  SEß t df p ICC 
(Intercept) 0.64 0.07 9.24 191 <.00005 0.162 
Day  0.03 0.03 1.09 191 0.14  
Amber Glasses 0.09 0.09 0.93 191 0.18  
Grey Glasses  -0.03 0.09 -0.33 191 0.37  
Washout  -0.35 0.29 -1.22 191 0.11  
Day*Amber Glasses -0.03 0.03 -0.97 191 0.17  
Day*Grey Glasses     -0.01 0.03 -0.46 191 0.32  










Figure 14. Ridgeline plots of WatchPAT extraneous sleep factors by condition: REM Latency, number of wakes, 
mean pulse, and mean oxygen saturation measured by WatchPAT by condition. The three red lines on each ridgeline 
plot indicate—from left to right—the first quartile, the median, and the third quartile. All four of the associated t-














Figure 15. Spaghetti plots for PANAS Positive Affect AM and PM and PANAS Negative Affect AM and PM 
outcome variables by condition. Trend lines are regressions for each participant showing changes in the outcome 
variable over the days in each condition. Colors represent the glasses conditions, the first panel represents baseline, 
and the fourth panel represents the washout phase. 







Figure 16. Spaghetti plots for PANAS Positive Affect AM and PM and PANAS Negative Affect AM and PM 
outcome variables by condition. Trend lines connect the data points for each participant showing changes in the 
outcome variable over the days in each condition. Panels 0 through 3 represent the baseline, amber glasses, grey 
glasses, and washout conditions, respectively.    
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Table 8.  
Beta Weights Predicting Positive Affect in AM as measured by PANAS 
      
Predictor  ß  SEß t df p ICC 
(Intercept) 0.38 0.04 10.10 208 <.00005 0.57 
Day  -0.00 0.01 -0.20 208 0.42  
Amber Glasses 0.01 0.04 0.32 208 0.37  
Grey Glasses  -0.00 0.04 -0.12 208 0.45  
Washout  0.05 0.12 0.38 208 0.35  
Day*Amber Glasses -0.00 0.01 -0.20 208 0.42  
Day*Grey Glasses     -0.00 0.01 -0.10 208 0.46  
Day*Washout -0.00 0.02 -0.28 208 0.39  
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Table 9.  
Beta Weights Predicting Positive Affect in PM as measured by PANAS 
      
Predictor  ß  SEß t df p ICC 
(Intercept) 0.38 0.04 10.64 199 <.00005 0.57 
Day  0.00 0.01 0.19 199 0.42  
Amber Glasses 0.08 0.04 2.03 199 0.02  
Grey Glasses  0.02 0.04 0.47 199 0.32   
Washout  -0.07 0.12 -0.61 199 0.27  
Day*Amber Glasses -0.01 0.01 -0.87 199 0.19  
Day*Grey Glasses     -0.01 0.01 -0.52 199 0.30  







AMBER GLASSES, SLEEP, & AFFECT 
 67 
Table 10.  
Beta Weights Predicting Negative Affect in AM as measured by PANAS 
      
Predictor  ß  SEß t df p ICC 
(Intercept) 0.25 0.01 22.86 208 <.00005 0.33 
Day  -0.01 0.00 -2.79 208 0.003  
Amber Glasses -0.03 0.01 -2.27 208 0.01  
Grey Glasses  -0.02 0.01 -1.65 208 0.05  
Washout  -0.06 0.04 -1.34 208 0.09  
Day*Amber Glasses 0.01 0.00 2.74 208 0.003  
Day*Grey Glasses     0.01 0.00 2.62 208 0.005  
Day*Washout 0.02 0.01 2.37 208 0.009  
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Table 11.  
Beta Weights Predicting Negative Affect in PM as measured by the PANAS 
      
Predictor  ß  SEß t df p ICC 
(Intercept) 0.23 0.02 14.64 199 <.00005 0.32 
Day  -0.00 0.01 -0.79 199 0.22  
Amber Glasses -0.02 0.02 -0.93 199 0.18  
Grey Glasses  -0.01 0.02 -0.61 199 0.27  
Washout  -0.03 0.06 -0.45 199 0.33  
Day*Amber Glasses 0.01 0.01 0.88 199 0.19  
Day*Grey Glasses     0.01 0.01 0.86 199 0.20  
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Figure 17. Pearson correlation matrix representing the agreement between multiple sleep duration (SD), sleep 
quality (SQ), and sleep latency (SL) measures. Significant correlations are filled-in and insignificant correlations are 
blank.  
 
 
 
 
 
 
 
